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Abstract 
 Subunit vaccines are a potential intervention strategy against leptospirosis, which is a major public health 
problem in developing countries. Thus far, several proteins have been evaluated as potential vaccine candidates, but 
all those tested in aluminum hydroxide adjuvant have failed to protect animals against lethal challenge. Seven new 
leptospiral lipoproteins were evaluated as vaccine candidates. The coding sequences of these lipoproteins were 
amplified by PCR from Leptospira interrogans serovar Copenhageni, strain Fiocruz L1-130, cloned and expressed 
in Escherichia coli. The purified proteins were adsorbed in aluminum adjuvant and used in the immunization of four 
to six weeks old hamsters. After two doses of 60 ȝg of recombinant protein, hamsters were challenged with a lethal 
dose of L. interrogans. All seven tested proteins failed to fully protect the animals from disease or death. Further 
study must be undertaken toward developing an efficient subunit vaccine against leptospirosis for humans, livestock 
and pets.  
© 2009 Elsevier B.V. 
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1. Introduction 
Leptospirosis is a bacterial disease that affects both humans and animals (29). It is found in a wide variety 
of environmental contexts, in industrialized and developing countries, and in urban and rural areas (2). The number 
of human and animal cases worldwide is not well-documented. During outbreaks and in high-risk groups, 100 or 
more per 100,000 may be infected and for several reasons leptospirosis is overlooked and consequently 
underreported (28). It is currently considered a neglected tropical bacterial disease (11). In developing countries, 
leptospirosis has become an urban health problem as slum settlements have grown and outbreaks in these 
communities have increased (12, 14, 21). In these settings, current control measures have been ineffective in 
addressing leptospirosis (16). Pathogenic Leptospira are highly invasive bacteria capable of infecting a broad range 
of mammalian hosts (5), and the host infection produces a diverse array of clinical manifestations (2). This infecting 
agent is transmitted from one animal carrier to another, or to humans, via direct or indirect contact with urine or 
other body fluids that contain viable leptospires (15).  
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 Current vaccines against leptospirosis target the lipopolysaccharide coat of leptospires, which has over 300 
serovars (1), and many different strains with small antigenic differences can be found in some serovars, thus limiting 
cross-protection (2). The identification of new targets expressed during infection is important for the development of 
new immunoprotective strategies (9). To date, there is incomplete knowledge on the mechanisms of protective 
immunity against leptospiral infection, and the current emphasis in research laboratories is to discover cross-species 
and cross-serovar-conserved protective antigens that may provide longer-term protection from a broad range of 
Leptospira (27) 
 Several recombinant outer membrane proteins (OMP) have been shown to be protective immunogens in 
animal models of bacterial diseases (7, 13, 26). Recombinant leptospiral OMPs such as OmpL1, LipL41, LipL32, 
and Leptospiral immunoglobulin-like protein A (LigA) have been evaluated as potential vaccine candidates (4, 6, 
10, 18). Our group has recently demonstrated that vaccination with a LigA fragment (24) or with a recombinant 
Mycobacterium bovis BCG expressing the LipL32 antigen (23), may constitute potential intervention strategy 
against leptospirosis. In the present study we evaluate eight recombinant proteins previously identified as potential 
subunit vaccine candidates (8). 
2. Protein production: cloning, expression and purification 
 L. interrogans serovar Copenhageni strain Fiocruz L1-130 (14, 17) was cultivated in Ellinghausen-
McCullough-Johnson-Harris (EMJH) liquid medium (Difco Laboratories) at 29 °C. Culture growth was monitored 
by counting in a Petroff-Hausser chamber (Fisher) and dark-field microscopy as previously described (5). 
Escherichia coli strains BL21 (DE3)-RIL and STAR were grown in Luria-Bertani (LB) medium at 37 °C (20). 
Primers were designed to include most of the target genes but not their highly hydrophobic signal sequences, they 
also included a restriction enzyme site. Coding sequences were amplified by PCR and cloned into the expression 
vectors pQE30 (Qiagen) or pAE (19). Recombinant plasmids were used to transform E. coli strains by 
electroporation and E. coli transformants containing the constructs were cultured at 37 °C. Expression was induced 
by isopropyl-ȕ-d-thiogalactopyranoside (IPTG), at 1 mM final concentration. The cells were harvested by 
centrifugation, resuspended in column buffer (8 M urea, 100 mM Tris, 300 mM NaCl, 5 mM imidazole, pH 8.0), 
and disrupted by sonication (3× 1 min pulses; Sonics & Material Inc.). His-tagged proteins were purified by affinity 
chromatography in a nickel (Ni+2) charged Sepharose column. Columns containing bound protein were washed with 
10 volumes of column buffer, then 6 × wash buffer (6 M urea, 100 mM Tris, 300 mM NaCl, pH 8.0) containing 
5 mM imidazole for the first three washes and increasing to 10 mM imidazole for the remaining washes. His-tagged 
proteins were eluted from the column with wash buffer containing 250 mM imidazole. Dialysis procedure was used 
to remove urea and imidazole and to promote refolding of the recombinant proteins. Proteins in the final preparation 
were quantified by the Bradford method (3). 
3. Imunization assays 
Female Golden Syrian hamsters 4-6 weeks old were allocated into groups of 6 animals and immunized by 
intramuscular route (I.M.) with recombinant protein in aluminum hydroxide (15%) on day 0 and day 14. 
Immunization was performed with two 60 ȝg doses of recombinant protein. Hamsters were immunized with 250 ȝL 
per injection site. A negative control group of hamsters was immunized with aluminum hydroxide adjuvant and 
PBS, and a positive control group was immunized with killed L. interrogans. Immunized hamsters were challenged 
at age 8-10 weeks, fourteen days after the second immunization, with an intraperitoneal (I.P.) administration of 100 
leptospires (~2 × LD50) of strain Fiocruz L1-130 (22). Hamsters were monitored daily for clinical signs of 
leptospirosis and euthanized when clinical signs of terminal disease appeared. Surviving hamsters were euthanized 
on day 24 post-challenge. Experimental animals were maintained at the animal facility of the Biotechnology Center 
of the Federal University of Pelotas (UFPel). The animals were manipulated in accordance with the University 
guidelines of the Ethics Committee in Animal Experimentation throughout the experimental period. 
4. Results and Discussion 
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All PCR products were successfully cloned and expressed in E. coli as a 6×His tag N-terminus fusion 
protein, which allows purification of the protein by affinity chromatography. All seven proteins were expressed as 
insoluble inclusion bodies. They were solubilized and purified using a buffer containing urea. After dialysis and 
SDS-PAGE, purity was estimated to be over 90%. The immunization assays failed to reveal a fully protective 
vaccine candidate. Although LIC12099 did fully protect in the first experiment, it failed to protect in a subsequent 
experiment. Another protein tested twice (in two different experiments), was LIC10508, because, although it did not 
fully protect, it delayed mortality (Table 1). 
Table 1. Protection conferred by immunization with recombinant lipoproteins against lethal challenge in the       
hamster model. 
Experiment Groupa Days until death no. survivors/total
LIC12099 - 6/6 d 
LIC12730 11,11,12,13,14,14 0/6 
LIC10561 11,11,11,11,13 1/6 
LIC10508 11,13,13,13,18 1/6 
Whole-cell preparationb - 6/6 d
1 
Control immunizationc 11,11,12,13,13,14 0/6 
LIC12099 10,13,13,13,14,14 0/6
LIC10191 10,10,10,10,11,13 0/6 
LIC10508 9,9,9,10,11,12 0/6 
Whole-cell preparation - 6/6 d
2 
Control immunization 9,9,9,10,11,11 0/6 
LIC10011 11,12,13,13,14 1/6 
LIC11947 12,12,14,14,16,17 0/6 
LIC12538 11,11,13,13,14 1/6 
Whole-cell preparation - 6/6d
3 
Control immunization 10,11,11,12,14 1/6 
a
 Animals were vaccinated twice (60/60 ȝg) at 2-week interval and were challenged with Fiocruz  L1-130 two week after the last vaccination. 
b
 Immunizations were performed with heat-inactivated preparations of L. interrogans Fiocruz L1-130. 
c
 Control immunizations were performed by administering PBS with aluminum hydroxide adjuvant. 
d
 Protection against lethal challenge was statistically significant (P <0.05). 
Extensive efforts have been made to identify cross-protective antigens of Leptospira (25, 27). Lipoproteins and 
other membrane associated proteins are potential vaccine candidates. However, only a few leptospiral proteins 
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characterized so far have been able to confer protection when used to immunize susceptible animals (10, 18, 23-24) 
but none of them were able to fully protect, when compared to control groups. In our study, in one case the ~2 × 
LD50 challenge was not able to kill the entire control group, this did not however mask false protecting proteins, as 
they also failed to protect.  
All experiments were undertaken in the same manner, therefore there would be no reason to attribute the lack of 
repeatability of the first results obtained with LIC12099, to experimental conditions. However, the same batch of 
proteins used in the first experiment was used in the second, and the storage period may have somehow modified the 
proteins tertiary structure, although no degradation was observed in SDS-PAGE. Other proteins, though not fully 
protective, were able to delay death in several cases, which may indicate protective potential, if parameters such as 
dose volume, interval and adjuvant are optimized. 
The mechanism of immune protection in leptospirosis remains unknown. There is need for studies directed 
towards defining how the immunity resulting from recombinant protein immunization can be improved. 
Determination of the relative contributions of humoral immune mechanisms and cellular-mediated immunity would 
provide insights about immune response against leptospirosis. Further experiments, evaluating other proteins, and 
probing leptospirosis associated immune response are currently being performed.  
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